Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on beh
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
11:18am, Thursday, 30'th Oct 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Contact The Gross Law Firm by November 17, 2025 Deadline to Join Class Action Against Cytokinetics, Incorporated(CYTK)
08:45am, Thursday, 30'th Oct 2025
NEW YORK , Oct. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during t
CYTOKINETICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds CYTK Investors to Contact the Firm Before November 17th
05:34pm, Wednesday, 29'th Oct 2025
The Complaint alleges Cytokinetics misled investors about aficamten's FDA approval timeline by omitting REMS risks that could delay the regulatory process.
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
04:41pm, Wednesday, 29'th Oct 2025
LOS ANGELES , Oct. 29, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYT
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
04:16pm, Wednesday, 29'th Oct 2025
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 an
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
11:32am, Wednesday, 29'th Oct 2025
LOS ANGELES, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline
11:10am, Wednesday, 29'th Oct 2025
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
10:20am, Wednesday, 29'th Oct 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If yo
NEW YORK and NEW ORLEANS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they h
Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments
04:32pm, Tuesday, 28'th Oct 2025
Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date.
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK
03:36pm, Tuesday, 28'th Oct 2025
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsui
Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market
03:08pm, Tuesday, 28'th Oct 2025
Robert Blum, Cytokinetics CEO, joins 'Power Lunch' to discuss the company's value proposition, what the company is working towards and much more.
